<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE333nnn/GSE333210/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE333210</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>ZEB1 K80R Suppresses the NF-κB/EMT Axis and Tumor Pro-inflammatory Gene Expression</name><description>This study demonstrates that ZEB1 K80 is a critical lysine residue acetylated by p300. Deacetylation of ZEB1 at K80 (K80R mutation) significantly suppresses the epithelial-mesenchymal transition (EMT) program and the expression of tumor inflammation-related genes, leading to downregulation of EMT markers (e.g., VIM, MMP9) and pro-inflammatory cytokines/chemokines (e.g., ICAM1, CCL5, CXCL8, CSF2, TNFα). Pathway enrichment analysis reveals that NF-κB signaling, inflammatory response, and EMT-related pathways are markedly inhibited. Collectively, our data provide key molecular insights into the role of ZEB1 acetylation in tumor progression: deacetylation at the K80 site of ZEB1 significantly attenuates tumor cell proliferation and metastasis.</description><dates><publication>2026/05/30</publication></dates><accession>GSE333210</accession><cross_references><GSM>GSM9759197</GSM><GSM>GSM9759195</GSM><GSM>GSM9759196</GSM><GPL>34284</GPL><GSE>333210</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>